Milestone Pharmaceuticals financials
$0.8200+3.09%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $559.0K | $238.0K | $1.5M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $527.0K | $224.0K | $1.5M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 94.3% | 94.1% | 100.0% | — | — | — | — | — | — | — | — | — |
| Operating income | -$25.6M | -$23.7M | -$17.3M | -$11.8M | -$12.5M | -$20.5M | -$12.3M | -$9.6M | -$9.7M | -$10.5M | -$13.8M | -$15.4M |
| Net income | -$28.6M | -$26.1M | -$17.4M | -$11.9M | -$13.0M | -$20.8M | -$12.4M | -$9.4M | -$9.4M | -$10.4M | -$13.6M | -$15.1M |
| Net margin | −5118.8% | −10952.1% | −1126.1% | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.21 | $-0.20 | $-0.16 | $-0.12 | $-0.20 | $-0.31 | $-0.19 | $-0.14 | $-0.14 | $-0.21 | $-0.32 | $-0.35 |
| EBITDA | -$25.6M | -$23.6M | -$17.2M | -$11.8M | -$12.5M | -$20.5M | -$12.3M | -$9.6M | -$9.6M | -$10.4M | -$13.8M | -$15.3M |
| Operating cash flow | -$22.7M | -$16.1M | -$12.8M | -$9.7M | -$12.6M | -$14.0M | -$6.8M | -$7.0M | -$6.1M | -$8.9M | -$9.8M | -$12.2M |
| Free cash flow | -$22.7M | -$16.1M | -$13.1M | -$9.8M | -$12.6M | -$14.0M | -$6.9M | -$7.0M | -$6.1M | -$8.9M | -$9.8M | -$12.2M |
| Diluted shares | 138.7M | 130.3M | 106.4M | 96.5M | 66.4M | 66.3M | 66.3M | 66.2M | 66.2M | 50.2M | 43.1M | 43.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $169.7M | $71.3M | $73.0M | $46.7M | $42.5M | $45.1M |
| Short-term investments | $881.0K | $112.9M | $32.9M | $35.9M | $918.0K | $10.9M |
| Total debt | $59.2M | $136.3M | $57.2M | $56.2M | $55.2M | $54.3M |
| Total assets | $181.6M | $193.7M | $113.6M | $87.8M | $47.4M | $61.9M |
| Total liabilities | $219.1M | $213.3M | $127.4M | $122.9M | $65.2M | $121.1M |
| Shareholders' equity | -$37.4M | -$19.6M | -$13.9M | -$35.1M | -$17.7M | -$59.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology